Cryptococcal meningitis (CM) is a severe fungal meningoencephalitis that primarily occurs in individuals with advanced HIV/AIDS in resource-limited settings. Despite scale-up of antiretroviral therapy (ART), HIV-associated CM resulted in an estimated 181,100 deaths in 2014 and up to 15% of HIV-related deaths worldwide. In ART-nave patients with CD4 T-cell counts <100 cells/L, asymptomatic cryptococcal antigenemia predicts cryptococcal meningitis and all-cause mortality. The World Health Organization (WHO) recommends cryptococcal antigen (CrAg) screening to detect early infection in ART-nave individuals with CD4<100 cells/L and targeted high-dose fluconazole in asymptomatic CrAg-positive patients followed by ART at 2 weeks or lumbar puncture (LP) to evaluate for CM in patients with symptoms of meningitis. Despite these recommendations, important questions remain on how to optimize CrAg screening strategies. First, a proportion of asymptomatic patients already have sub-clinical meningitis and may receive inferior therapy with fluconazole rather than amphotericin B- based treatment for meningeal disease. Secondly, there is an absence of outcomes data for CrAg screening in ART-experienced patients, who are likely to become a growing population with adoption of HIV ?test-and-treat? strategies with ART increasingly initiated in the absence of CD4 count or CrAg results. In a pragmatic prospective cohort, we will perform laboratory-based CrAg screening of HIV- infected patients with CD4 counts <100 cells/L in Botswana, a country that recently adopted HIV test- and-treat. We will prospectively follow CrAg-positive patients in clinic to screen for meningitis with LP and start patients without meningitis on high-dose fluconazole according to guidelines or refer patients with meningitis for hospitalization. Six-month incident CM and all-cause mortality will be compared between CrAg-positive ART-nave and ART-experienced patients, as well as a CD4-matched CrAg- negative comparator group, and cost-effectiveness evaluated in the context of observed HIV test-and- treat adoption. Secondly, we will validate a novel point-of-care CrAg lateral flow assay (LFA), CryptoPS (Biosynex S.A.), which provides a semi-quantitative CrAg titer instead of binary (positive/negative) result of the commercially available LFA (IMMY, Norman, OK). High CrAg titers have been shown to predict sub-clinical meningitis, and we will determine the sensitivity and specificity of high CryptoPS titer for identifying sub-clinical meningitis as well as predicting 6-month mortality. This study will: 1) provide important insights into CrAg screening utility, cost-effectiveness and outcomes in the era of HIV test- and-treat; and 2) with validation of a semi-quantitative CrAg assay, may lead to important refinements in CrAg testing strategies that incorporate point-of-care CrAg titer results for stratified patient management.

Public Health Relevance

In a prospective cohort study in Botswana of patients with advanced HIV (CD4 <100 cells/L), we will perform laboratory-based screening for cryptococcal infection using a cryptococcal antigen (CrAg) lateral flow assay (LFA). We will validate a novel semi-quantitative LFA against the current gold standard LFA with binary readout, determine predictive value of high semi-quantitative titer for determining cryptococcal meningitis and 6-month mortality, and evaluate 6-month clinical outcomes of antiretroviral therapy (ART)-nave and ART-experienced patients with active case management and pre- emptive high-dose fluconazole.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Postdoctoral Individual National Research Service Award (F32)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Love, Dona
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code